Phase 1, Randomized, Placebo-Controlled, Observer Blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an Investigational Self-Amplifying mRNA Influenza Vaccine in Healthy Adults
Latest Information Update: 29 Nov 2024
At a glance
- Drugs Self-amplifying-mRNA-influenza-virus-vaccine-A(H1N1) (Primary) ; Self-amplifying-mRNA-influenza-virus-vaccine-A(H5N1) (Primary)
- Indications Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Seqirus
Most Recent Events
- 27 Nov 2024 Status changed from active, no longer recruiting to completed.
- 19 Sep 2024 Planned End Date changed from 24 Sep 2024 to 15 Oct 2024.
- 19 Sep 2024 Planned primary completion date changed from 24 Sep 2024 to 15 Oct 2024.